Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy

Zeruesenay Desta, Roseann S. Gammal, Li Gong, Michelle Whirl-Carrillo, Aditya H. Gaur, Chonlaphat Sukasem, Jennifer Hockings, Alan Myers, Marelize Swart, Rachel F. Tyndale, Collen Masimirembwa, Otito F. Iwuchukwu, Sanika Chirwa, Jeffrey Lennox, Andrea Gaedigk, Teri E. Klein, David W. Haas

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.

Original languageEnglish (US)
Pages (from-to)726-733
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume106
Issue number4
DOIs
StatePublished - Oct 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Desta, Z., Gammal, R. S., Gong, L., Whirl-Carrillo, M., Gaur, A. H., Sukasem, C., Hockings, J., Myers, A., Swart, M., Tyndale, R. F., Masimirembwa, C., Iwuchukwu, O. F., Chirwa, S., Lennox, J., Gaedigk, A., Klein, T. E., & Haas, D. W. (2019). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clinical Pharmacology and Therapeutics, 106(4), 726-733. https://doi.org/10.1002/cpt.1477